Optimized Page
Menarini Stemline is collaborating with Outcomes4Me to raise awareness of ESR1 mutation testing
Nearly 1 out of 2 people
with ER+/HER2- metastatic breast cancer may develop an ESR1 mutation after progression on hormone therapy.
MAT-US-DS-00285 11/24
